20th May 2015 08:44
LONDON (Alliance News) - Cambridge Cognition Holdings PLC on Wednesday said it has launched a cloud-based cognitive assessment product with a view to accelerating treatments for Alzheimer's disease.
The company said the Cantab Connect Alzheimer's product provides sensitive measures which it claims are significantly more effective than paper-based tests.
"Cambridge Cognition has become synonymous with innovation in healthcare, research and development for Alzheimer's. Today we launch the first in a series of cognitive assessment software products to support effective development of new drugs across a range of disease areas," said Chief Executive Nick Kerton.
Shares in Cambridge Cognition were untraded Wednesday, having last traded at 80.00 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Cambridge Cog